Condition: Breast Cancer Invasive · Metastatic Cancer · Oligoprogressive · Sponsor: The Netherlands Cancer Institute
Patients with oligoprogression of metastatic breast cancer during palliative treatment that is amenable to local therapy will be included. The local ablative therapy (LAT) may consist of stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy, surgery or radiofrequency ablation (RFA).
This description comes directly from the study's public registry record.
G Sonke, MD · +31-20-512 · g.sonke@nki.nl
A Almekinders · c.almekinders@nki.nl
Always discuss trial participation with your own doctor first.
| Noordwest Ziekenhuisgroep | Alkmaar, Netherlands | Not Yet Recruiting |
| Antoni van Leeuwenhoek | Amsterdam, Netherlands | Recruiting |
| Rijnstate | Arnhem, Netherlands | Recruiting |
| Deventer ziekenhuis | Deventer, Netherlands | Not Yet Recruiting |
| ADRZ | Goes, Netherlands | Recruiting |
| Martini ziekenhuis | Groningen, Netherlands | Not Yet Recruiting |
| Antonius ziekenhuis | Utrecht, Netherlands | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05301881